CN109952305A - 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用 - Google Patents

哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN109952305A
CN109952305A CN201880004423.7A CN201880004423A CN109952305A CN 109952305 A CN109952305 A CN 109952305A CN 201880004423 A CN201880004423 A CN 201880004423A CN 109952305 A CN109952305 A CN 109952305A
Authority
CN
China
Prior art keywords
alkyl
compound
heteroaryl
aryl
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004423.7A
Other languages
English (en)
Other versions
CN109952305B (zh
Inventor
李心
何威
陈阳
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN109952305A publication Critical patent/CN109952305A/zh
Application granted granted Critical
Publication of CN109952305B publication Critical patent/CN109952305B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明涉及哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用。特别地，本发明涉及通式(I)所示的哌嗪并杂芳基类衍生物、其制备方法、含有该衍生物的药物组合物，以及其作为衣壳蛋白抑制剂，特别是在预防和/或治疗乙型肝炎、流感、疱疹和艾滋病等疾病中的用途。其中通式(I)中的各基团的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN201880004423.7A 2017-07-27 2018-07-26 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用 Active CN109952305B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017106217449 2017-07-27
CN201710621744 2017-07-27
CN201711058986 2017-11-01
CN2017110589868 2017-11-01
PCT/CN2018/097170 WO2019020070A1 (zh) 2017-07-27 2018-07-26 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN109952305A true CN109952305A (zh) 2019-06-28
CN109952305B CN109952305B (zh) 2022-06-21

Family

ID=65040957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880004423.7A Active CN109952305B (zh) 2017-07-27 2018-07-26 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用

Country Status (11)

Country Link
US (1) US11247998B2 (zh)
EP (1) EP3660018A4 (zh)
JP (1) JP2020528062A (zh)
KR (1) KR20200032702A (zh)
CN (1) CN109952305B (zh)
AU (1) AU2018305614B2 (zh)
BR (1) BR112020001299A2 (zh)
CA (1) CA3070004A1 (zh)
RU (1) RU2745431C1 (zh)
WO (1) WO2019020070A1 (zh)
ZA (1) ZA201908609B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113039186A (zh) * 2018-11-02 2021-06-25 艾库里斯有限及两合公司 抗乙型肝炎病毒HBV的脲6,7-二氢-4H-吡唑并[1,5-a]吡嗪活性剂
CN114146582A (zh) * 2021-11-30 2022-03-08 南京工业大学 一种氟化zif-90改性pdms膜的制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR116947A1 (es) * 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
CN111484497B (zh) * 2019-01-25 2021-07-02 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法
CN111484498B (zh) * 2019-01-25 2021-05-14 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法
MX2021008929A (es) * 2019-01-25 2021-08-24 Jiangsu Hengrui Medicine Co Forma cristalina de un derivado de 1,2,3-triazolo[1,5-a]pirazinas, y metodo de preparacion para la forma de cristal.
BR112021021564A2 (pt) 2019-04-30 2022-01-04 Aicuris Gmbh & Co Kg Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv)
JP2022533008A (ja) 2019-04-30 2022-07-21 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性な新規のオキサリルピペラジン
WO2020221824A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
JP2022531199A (ja) 2019-04-30 2022-07-06 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性な新規のフェニル及びピリジル尿素
CN112778299B (zh) * 2019-11-04 2023-07-14 江苏恒瑞医药股份有限公司 哌嗪脲基类衍生物、其制备方法及其在医药上的应用
WO2022022613A1 (zh) * 2020-07-29 2022-02-03 江苏恒瑞医药股份有限公司 一种三氮唑并[1，5-a]吡嗪制备方法及其应用
CN114057745A (zh) * 2020-07-29 2022-02-18 江苏恒瑞医药股份有限公司 一种三氮唑并[1,5-a]吡嗪制备方法及其应用
EP4229062A1 (en) 2020-10-15 2023-08-23 Aligos Therapeutics, Inc. Bicyclic compounds
TW202245772A (zh) * 2021-02-04 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種衣殼蛋白抑制劑的醫藥組成物及其製備方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100391958C (zh) * 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
CN101686989A (zh) * 2007-06-21 2010-03-31 卡拉治疗学股份有限公司 取代的咪唑并杂环
CN103168041A (zh) * 2010-06-03 2013-06-19 赛诺菲 3,4-二氢吡咯并[1,2-a]吡嗪-2,8(1h)-二甲酰胺衍生物、其制备方法及其治疗用途
WO2016113273A1 (en) * 2015-01-16 2016-07-21 F. Hoffmann-La Roche Ag Pyrazine compounds for the treatment of infectious diseases
CN105916855A (zh) * 2013-11-14 2016-08-31 百时美施贵宝公司 作为酪蛋白激酶1d/e抑制剂的取代的4,5,6,7-四氢吡唑并[1,5-a]吡嗪衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10012824A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
MY147757A (en) * 2007-03-09 2013-01-15 Sanofi Aventis Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
GB201010422D0 (en) 2010-06-22 2010-08-04 Univ Cardiff Cartilage repair
CN102464661B (zh) 2010-11-16 2015-04-01 天津药明康德新药开发有限公司 一种5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸乙酯的制备方法
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PL2888241T3 (pl) 2012-08-24 2017-12-29 Sunshine Lake Pharma Co., Ltd. 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekłego zapalenia wątroby
CN102875270B (zh) 2012-09-24 2014-12-03 巨化集团公司 一种三氟甲基代胺的合成方法
LT3024819T (lt) 2013-07-25 2018-06-11 Janssen Sciences Ireland Uc Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui
EA035848B1 (ru) 2014-02-06 2020-08-20 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
WO2016016196A1 (en) 2014-07-31 2016-02-04 F. Hoffmann-La Roche Ag Novel chiral resolution of 4-aryl-2-thiazol-2-yl-1,4-dihydropyrimidine-5-carboxylic acid esters
BR112018009009A8 (pt) 2015-11-03 2019-02-26 Hoffmann La Roche terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CN109153682B (zh) 2016-05-20 2021-05-25 豪夫迈·罗氏有限公司 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100391958C (zh) * 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
CN101686989A (zh) * 2007-06-21 2010-03-31 卡拉治疗学股份有限公司 取代的咪唑并杂环
CN103168041A (zh) * 2010-06-03 2013-06-19 赛诺菲 3,4-二氢吡咯并[1,2-a]吡嗪-2,8(1h)-二甲酰胺衍生物、其制备方法及其治疗用途
CN105916855A (zh) * 2013-11-14 2016-08-31 百时美施贵宝公司 作为酪蛋白激酶1d/e抑制剂的取代的4,5,6,7-四氢吡唑并[1,5-a]吡嗪衍生物
WO2016113273A1 (en) * 2015-01-16 2016-07-21 F. Hoffmann-La Roche Ag Pyrazine compounds for the treatment of infectious diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PUBCHEM: "PubChem CID 90793128", 《PUBCHEM》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113039186A (zh) * 2018-11-02 2021-06-25 艾库里斯有限及两合公司 抗乙型肝炎病毒HBV的脲6,7-二氢-4H-吡唑并[1,5-a]吡嗪活性剂
CN114146582A (zh) * 2021-11-30 2022-03-08 南京工业大学 一种氟化zif-90改性pdms膜的制备方法

Also Published As

Publication number Publication date
AU2018305614B2 (en) 2022-05-12
US20200157111A1 (en) 2020-05-21
BR112020001299A2 (pt) 2020-07-28
US11247998B2 (en) 2022-02-15
CA3070004A1 (en) 2019-01-31
JP2020528062A (ja) 2020-09-17
RU2745431C1 (ru) 2021-03-25
EP3660018A1 (en) 2020-06-03
CN109952305B (zh) 2022-06-21
WO2019020070A1 (zh) 2019-01-31
AU2018305614A1 (en) 2020-03-05
ZA201908609B (en) 2022-07-27
EP3660018A4 (en) 2021-04-21
KR20200032702A (ko) 2020-03-26

Similar Documents

Publication Publication Date Title
CN109952305A (zh) 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用
WO2021027911A1 (zh) 新型螺环类K-Ras G12C抑制剂
CN111527099A (zh) 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
TW202115076A (zh) 嘧啶并五員氮雜環類衍生物、其製備方法及其在醫藥上的應用
WO2021000885A1 (zh) 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
TW201927789A (zh) B型肝炎抗病毒試劑
CN112585118A (zh) 乙型肝炎衣壳装配调节剂
WO2020238791A1 (zh) 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
AU2017367714B2 (en) Tricyclic heterocycle compounds useful as HIV integrase inhibitors
CN107531679A (zh) 芳香酰胺类衍生物、其制备方法及其在医药上的应用
CN108473494A (zh) 作为hiv整合酶抑制剂的稠合三环杂环化合物
CN111386275B (zh) 高活性sting蛋白激动剂
TWI723511B (zh) 一種高活性sting蛋白激動劑化合物
WO2019137201A1 (zh) 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
WO2020244539A1 (zh) 吡啶酮类衍生物、其制备方法及其在医药上的应用
WO2021027647A1 (zh) 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
JP2021529159A (ja) Ｎ−置換テトラヒドロチエノピリジン誘導体及びその使用
WO2023066371A1 (zh) 含氮的四环化合物、其制备方法及其在医药上的应用
EP3720859A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP4174068A1 (en) Novel compound, and pharmaceutical composition for preventing or treating resistant cancer, comprising same
CN112300161B (zh) 一类用于治疗和/或预防乙型肝炎病毒感染的化合物及其制备方法和应用
TW201910333A (zh) 哌嗪并雜芳基類衍生物、其製備方法及其在醫藥上的應用
WO2024104435A1 (zh) 三并环类PI3Kα抑制剂及其制备方法和医药用途
CN115043836A (zh) 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
WO2024099225A1 (zh) Ulk抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40009386

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant